Patents Assigned to National Cancer Center
-
Patent number: 12043872Abstract: This application provides a kit or a device for detection of lung cancer, comprising a nucleic acid(s) for detecting a miRNA(s) in a sample from a subject, and a method for detecting lung cancer, comprising measuring the miRNA(s) in vitro.Type: GrantFiled: March 10, 2023Date of Patent: July 23, 2024Assignees: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTERInventors: Yuho Kida, Satoko Kozono, Hiroko Sudo, Satoshi Kondou, Junpei Kawauchi, Takahiro Ochiya, Shun-ichi Watanabe
-
Publication number: 20240218455Abstract: An object of the present invention is to provide a kit or a device for the detection of prostate cancer and a method for detecting prostate cancer. The present invention provides a kit or a device for the detection of prostate cancer, comprising a nucleic acid capable of specifically binding to a miRNA in a sample of a subject, and a method for detecting prostate cancer, comprising measuring the miRNA in vitro.Type: ApplicationFiled: March 14, 2024Publication date: July 4, 2024Applicants: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTERInventors: Satoshi KONDOU, Hitoshi NOBUMASA, Satoko KOZONO, Hiroko SUDO, Junpei KAWAUCHI, Takahiro OCHIYA, Nobuyoshi KOSAKA
-
Publication number: 20240209108Abstract: An object of the present invention is to provide an anti-CLDN4/anti-CD137 bispecific antibody usable in treatment of cancer. An anti-CLDN4/anti-CD137 bispecific antibody produced using an anti-CLDN4 antibody binding to CLDN4 and an anti-CD137 antibody binding to CD137 had agonistic activity for CD137, promoted production of interferon ? by a T cell, and exhibited cytotoxic activity against a cancer cell expressing CLDN4 on a cell surface thereof. Besides, it was shown that the anti-CLDN4/anti-CD137 bispecific antibody can be safely administered to monkeys. Therefore, the anti-CLDN4/anti-CD137 bispecific antibody is usable in treatment of human cancer.Type: ApplicationFiled: April 21, 2022Publication date: June 27, 2024Applicants: Astellas Pharma Inc., National Cancer CenterInventors: Yoshiyuki TENDA, Masatoshi YURI, Shigenori YAGI, Yoshiki SATAKE, Kazunori HIRAYAMA, Hiroki SHIRAI, Hiroki SASAKI, Fumiko CHIWAKI, Masayuki KOMATSU
-
Publication number: 20240206700Abstract: An information processing apparatus (2000) detects an abnormal region (30) from a moving image frame (14). The abnormal region (30) is a region that is estimated to represent an abnormal part inside a body of a subject. The information processing apparatus (2000) generates and outputs output information based on the number of detected abnormal regions (30).Type: ApplicationFiled: March 11, 2024Publication date: June 27, 2024Applicants: NEC CORPORATION, National Cancer CenterInventors: Ikuma TAKAHASHI, Maki Sano, Kimiyasu Takoh, Motoyasu Okutsu, Chiemi Tanaka, Masahiro Saikou, Hitoshi Imaoka, Kenichi Kamijo, Ryuji Hamamoto, Yutaka Saito, Masayoshi Yamada
-
Patent number: 12012638Abstract: It is intended to provide a kit or a device for the detection of esophageal cancer and a method for detecting esophageal cancer. The present invention provides a kit or a device for the detection of esophageal cancer, comprising nucleic acid(s) capable of specifically binding to miRNA(s) in a sample of a subject, and a method for detecting esophageal cancer, comprising measuring the miRNA in vitro.Type: GrantFiled: November 18, 2022Date of Patent: June 18, 2024Assignees: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTERInventors: Hiroko Sudo, Hitoshi Nobumasa, Satoko Kozono, Satoshi Kondou, Junpei Kawauchi, Atsushi Ochiai, Motohiro Kojima
-
Publication number: 20240186005Abstract: There is provided an apparatus for predicting hypotension of a subject. The apparatus comprises a memory configured to store one or more instructions and a pre-trained hypotension prediction model; and a processor configured to execute the one or more instructions stored in the memory, wherein the instructions, when executed by the processor, cause the processor to: determine an arterial blood pressure data of the subject, input the arterial blood pressure data of the subject into the hypotension prediction model, and determine whether the subject has hypotension using an output result of the hypotension prediction model.Type: ApplicationFiled: February 12, 2024Publication date: June 6, 2024Applicants: THE ASAN FOUNDATION, NATIONAL CANCER CENTER, UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATIONInventors: Sunghoon KIM, Yongseok PARK, Junetae KIM, Eugene HWANG
-
Publication number: 20240183875Abstract: It is intended to provide a kit or a device for the detection of lung cancer and a method for detecting lung cancer. The present invention provides a kit or a device for the detection of lung cancer, comprising a nucleic acid capable of specifically binding to a miRNA in a sample from a subject, and a method for detecting lung cancer, comprising measuring the miRNA in vitro.Type: ApplicationFiled: January 5, 2024Publication date: June 6, 2024Applicants: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTERInventors: Hiroko SUDO, Hitoshi NOBUMASA, Satoko KOZONO, Satoshi KONDOU, Junpei KAWAUCHI, Atsushi OCHIAI, Motohiro KOJIMA
-
Patent number: 11998543Abstract: The present disclosure relates to a pharmaceutical composition for treating brain cancer containing an aldehyde inhibitor and an anticancer drug. Since there are many types of brain cancer and the boundary between brain cells and tumor cells in brain cancer is not clear, brain cancer is particularly difficult to treat. The pharmaceutical composition of the present disclosure may further contain a biguanide-based compound as needed, wherein the compound is preferably phenformin. The pharmaceutical composition of the present disclosure is very effective for the treatment and improvement of prognosis of brain cancer, and has remarkable effects of killing cancer cells and inhibiting cancer stem cell characteristics, compared to when each of the active ingredients is administered alone. Thus, it is expected that the pharmaceutical composition of the present disclosure will be widely used in the field of brain cancer treatment.Type: GrantFiled: May 17, 2019Date of Patent: June 4, 2024Assignees: Industry-Academic Cooperation Foundation, Yonsei University, National Cancer CenterInventors: Seok-Gu Kang, Soo Youl Kim
-
Patent number: 11998187Abstract: A suture method includes a first arrangement step of using a first treatment device including first/second grasping pieces to hook the first grasping piece to a first position of peripheral tissues of a lesion; a second arrangement step of hooking the second grasping piece to a second position of the peripheral tissues; a grasping step of grasping the first position and the second position while pressing the first position and the second position to the peripheral tissues; a retracting step of retracting the lesion site toward a proximal end side of the first treatment device while drawing the first position and the second position grasped by the first treatment device; and a suturing step of suturing a first suturing position at an external side of the first position and a second suturing position at an external side of the second position in the peripheral tissues.Type: GrantFiled: September 10, 2021Date of Patent: June 4, 2024Assignees: OLYMPUS CORPORATION, NATIONAL CANCER CENTERInventors: Chisato Karasawa, Satoru Nonaka, Ichiro Oda
-
Publication number: 20240166736Abstract: An objective of the present invention is to provide an anti-TSPAN8/anti-CD3 bispecific antibody and an anti-TSPAN8 antibody usable in treatment or prevention in human. A human monoclonal antibody producing mouse was immunized with a peritoneal disseminated cancer cell isolated from a patient, to obtain an antibody 16B11 and an antibody 16B12 that selectively bind to a peritoneal disseminated cancer cell. These antibodies were anti-TSPAN8 antibodies that bind to the region from amino acid positions 126 to 155 of TSPAN8 and exhibited strong binding activity to TSPAN8 expressed in the peritoneal disseminated cancer cell. Further, an anti-TSPAN8(16B11)-anti-CD3 bispecific antibody produced based on the sequence of 16B11 exhibited a cytotoxic activity against the TSPAN8-expressing cancer cell in vitro, exerted an anti-tumor action on TSPAN8-expressing cancer cell-bearing mice in vivo, and extended the lifetime of peritoneal dissemination model mice.Type: ApplicationFiled: December 26, 2023Publication date: May 23, 2024Applicants: Astellas Pharma Inc., National Cancer CenterInventors: Yoshiyuki TENDA, Masatoshi YURI, Daisuke YAMAJUKU, Takeshi TSUTSUMI, Yuko KUSUZAKI, Hiroki SASAKI, Fumiko CHIWAKI, Masayuki KOMATSU
-
Publication number: 20240168026Abstract: The present invention provides a convenient and noninvasive detection method for assisting in the determination of pancreatic cystic tumor to be benign or malignant, and a kit for detection therefor. Specifically, the present invention provides a method for assisting in the determination of malignant pancreatic cystic tumor, the method comprising the steps of measuring in vitro the amount of APOA2-AT protein or/and APOA2-ATQ protein present in a body fluid sample of a test subject having pancreatic cystic tumor, and assisting in determining the pancreatic cystic tumor to be benign or malignant on the basis of the amount, and a kit for assisting in the determination of malignant pancreatic cystic tumor, the kit being directed to measuring the amount of APOA2-AT protein or/and APOA2-ATQ protein and being usable in the method.Type: ApplicationFiled: March 22, 2022Publication date: May 23, 2024Applicants: Toray Industries, Inc., NATIONAL CANCER CENTERInventors: Michimoto Kobayashi, Hideki Kawai, Asako Sogame, Kazufumi Honda
-
Publication number: 20240141439Abstract: This invention provides a kit or device for detection of prostate cancer and a method for detecting prostate cancer. This invention provides a kit or device for detection of prostate cancer comprising a nucleic acid capable of specifically binding to an miRNA in a sample from a subject or a complementary strand thereof and a method for detecting prostate cancer comprising measuring the miRNA in vitro.Type: ApplicationFiled: January 9, 2024Publication date: May 2, 2024Applicants: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTERInventors: Makiko YOSHIMOTO, Hiroko SUDO, Atsuko MIYANO, Satoko KOZONO, Takahiro OCHIYA, Hiroyuki FUJIMOTO, Fumihiko URABE, Juntaro MATSUZAKI
-
Publication number: 20240122941Abstract: The present disclosure provides a pharmaceutical composition for treating and/or preventing SWI/SNF complex-dysfunction cancer. More specifically, according to the present disclosure, a compound represented by formulae (1) to (23) (the formulae are as set forth in the specification) or a pharmaceutically acceptable salt thereof can have a therapeutic and/or prophylactic effect on SWI/SNF complex-dysfunction cancer. A pharmaceutical composition, which is for treating and/or preventing cancer and contains a CBP/P300 inhibitor, can be provided. The cancer may be SWI/SNF complex-dysfunction cancer. The SWI/SNF complex-dysfunction cancer may be BAF complex-dysfunction cancer. The BAF complex-dysfunction cancer may be SMARC-deficient cancer, ARID-deficient cancer, or SS18-SSX fusion cancer. The SMARC-deficient cancer may be SMARCB1-deficient cancer, SMARCA2-deficient cancer, SMARCA4-deficient cancer, or SMARCA2/A4-deficient cancer.Type: ApplicationFiled: December 24, 2021Publication date: April 18, 2024Applicants: NATIONAL CANCER CENTER, Sumitomo Pharma Co., Ltd.Inventors: Hideaki OGIWARA, Mariko SASAKI
-
Publication number: 20240123092Abstract: Provided is a conjugate for photodynamic diagnosis or treatment in which a peptide binds with a photosensitizer via an intracellularly degradable linkage, and a composition for photodynamic diagnosis or treatment including the same. The conjugate generates no fluorescent signal and reactive oxygen in normal tissues or during the circulation in the blood by quenching a fluorescent signal and reactive oxygen generation ability of the photosensitizer. After the conjugate is selectively absorbed into target cells, a linker is degraded in cells to increase the distance between tryptophan included in the peptide and the photosensitizer, and the quenching action is terminated to generate a strong fluorescence signal and induce active generation of reactive oxygen. The conjugate has high tissue permeability, shows a high photodynamic therapeutic effect in only target cells while being safe in normal cells, and can obtain a good diagnostic image having a high ratio of target signal to background.Type: ApplicationFiled: September 15, 2023Publication date: April 18, 2024Applicant: NATIONAL CANCER CENTERInventors: Yong-Doo CHOI, Ji-Su Kim, Hyun Jin Kim
-
Patent number: 11959144Abstract: An object of the present invention is to provide a kit or a device for the detection of prostate cancer and a method for detecting prostate cancer. The present invention provides a kit or a device for the detection of prostate cancer, comprising a nucleic acid capable of specifically binding to a miRNA in a sample of a subject, and a method for detecting prostate cancer, comprising measuring the miRNA in vitro.Type: GrantFiled: October 31, 2022Date of Patent: April 16, 2024Assignees: Toray Industries, Inc., National Cancer CenterInventors: Satoshi Kondou, Hitoshi Nobumasa, Satoko Kozono, Hiroko Sudo, Junpei Kawauchi, Takahiro Ochiya, Nobuyoshi Kosaka
-
Patent number: 11957300Abstract: An information processing apparatus (2000) detects an abnormal region (30) from a moving image frame (14). The abnormal region (30) is a region that is estimated to represent an abnormal part inside a body of a subject. The information processing apparatus (2000) generates and outputs output information based on the number of detected abnormal regions (30).Type: GrantFiled: September 6, 2019Date of Patent: April 16, 2024Assignees: NEC CORPORATION, NATIONAL CANCER CENTERInventors: Ikuma Takahashi, Maki Sano, Kimiyasu Takoh, Motoyasu Okutsu, Chiemi Tanaka, Masahiro Saikou, Hitoshi Imaoka, Kenichi Kamijo, Ryuji Hamamoto, Yutaka Saito, Masayoshi Yamada
-
Publication number: 20240111804Abstract: A processor receives an input of finding information indicating at least one finding, which is desired to be searched for, on a query base image, which includes a part desired to be searched for and is a source of a query image, to derive the query image to which the finding has been added, derives at least one added finding feature amount indicating an image feature for the added finding, and derives a query normal feature amount indicating an image feature for a normal region included in the part in the query base image. The processor derives similarities between the query image and a plurality of reference images including findings on the basis of comparisons between the added finding feature amount and the query normal feature amount and the like with reference to an image database in which the plurality of reference images have been registered and extracts the reference image that is similar to the query image as a similar image from the image database on the basis of the similarities.Type: ApplicationFiled: December 14, 2023Publication date: April 4, 2024Applicants: NATIONAL CANCER CENTER, FUJIFILM CorporationInventors: Kazuma KOBAYASHI, Mototaka MIYAKE, Ryuji HAMAMOTO
-
Publication number: 20240101678Abstract: Provided are CAR-T compositions that are directed to HLA-DR. Certain provided HLA-DR CAR compositions exhibit low affinity for a polymorphic region of HLA-DR of a subject. Various in vitro and in vivo methods and reagents related to HLA-DR CAR-T are also provided. Methods described herein can include, for example, characterization of HLA-DR binding, proliferation of T-cells, as well as prevention and/or therapeutic treatment of cancer using a HLA-DR CAR-T composition provided herein.Type: ApplicationFiled: June 12, 2023Publication date: March 28, 2024Applicants: EUTILEX CO., LTD., NATIONAL CANCER CENTERInventors: Byoung S. KWON, Chungyong HAN
-
Publication number: 20240102108Abstract: Disclosed is a kit or a device for the detection of stomach cancer and a method for detecting stomach cancer, and provides a kit or a device for the detection of stomach cancer, including a nucleic acid(s) capable of specifically binding to a miRNA(s) in a sample from a subject, and a method for detecting stomach cancer, including measuring the miRNA(s) in vitro.Type: ApplicationFiled: November 15, 2023Publication date: March 28, 2024Applicants: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTERInventors: Satoko KOZONO, Hitoshi NOBUMASA, Satoshi KONDOU, Hiroko SUDO, Junpei KAWAUCHI, Atsushi OCHIAI, Motohiro KOJIMA
-
Publication number: 20240093311Abstract: It is intended to provide a kit or a device for the detection of breast cancer and a method for detecting breast cancer. The present invention provides a kit or a device for the detection of breast cancer, comprising nucleic acid(s) capable of specifically binding to a miRNA in a sample of a subject, and a method for detecting breast cancer, comprising measuring the miRNA in vitro.Type: ApplicationFiled: November 20, 2023Publication date: March 21, 2024Applicants: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTERInventors: Satoshi KONDOU, Hitoshi NOBUMASA, Satoko KOZONO, Hiroko SUDO, Junpei KAWAUCHI, Takahiro OCHIYA, Nobuyoshi KOSAKA, Makiko ONO, Kenji TAMURA